[Long-term prognostic value of lowering in free triiodothyronine in patients with hypertrophic cardiomyopathy].

Objective: To determine whether thyroid hormone (TH) level could also be an independent and incremental predictor of adverse events in patients with hypertrophic cardiomyopathy (HCM). Methods: A total of 982 consecutive patients with HCM at the National Center for Cardiovascular Diseases (China) from October 2009 to December 2013 were included in the present study, and followed up till the end of December 2016. The patients were divided into three groups according to the levels of free triiodothyronine (FT3 ): the group 1 (FT3 ≤4.28 pmol/L, n= 335), the group 2 (FT3 >4.28-<4.79 pmol/L, n= 310), and the group 3 (FT3 4.79-6.30 pmol/L, n= 337). Results: After a follow-up period of (53.8±14.1) months, 39 patients (4.0%) either suffered death with all causes or received a cardiac transplantation (7.8%, 2.9% and 1.2% of the patients in the group 1, group 2 and group 3, respectively). A multivariable Cox regression analysis revealed that FT3 ≤4.28 pmol/L was associated with a significantly higher risk of all-cause mortality or cardiac transplantation ( HR 8.83, 95% CI 1.115- 69.905, P= 0.039) in HCM patients. Conclusions: Low levels of FT3 is a risk factor of adverse events for patients with HCM, indicting a role of FT3 as a marker for assessing the risk of long-term adverse events in these patients.